| Bioactivity | DHODH-IN-23 (Compound A) is an orally active DHODH inhibitor that can be used for the research of cancer[1]. | ||||||||||||
| Invitro | DHODH-IN-23 (Compound A; 72 h) 抑制急性髓系白血病细胞增殖[1]。DHODH-IN-23 (0.1-3 μM; 72 h) 诱导 THP-1 细胞中 CDllb 的表达[1]。 Cell Proliferation Assay[1] Cell Line: | ||||||||||||
| In Vivo | DHODH-IN-23 (Compound A; 30 mg/kg; oral; twice daily for 21 days) 在 MV411 小鼠异种移植模型中显示出抗肿瘤活性[1]。 Animal Model: | ||||||||||||
| Name | DHODH-IN-23 | ||||||||||||
| CAS | 1346705-53-0 | ||||||||||||
| Formula | C24H21ClFNO4 | ||||||||||||
| Molar Mass | 441.88 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Srikant Viswanadha, et al. Compositions comprising a dhodh inhibitor for the treatment of acute myeloid leukemia. Patent WO2021079273A1. |